Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
Date:2/7/2013

ALISO VIEJO, Calif., Feb. 7, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three months ended December 31, 2012.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

Quarterly Financial Highlights

  • Total company net revenues increased to $16.5 million, representing growth of 22% versus the previous quarter
  • Gross and net NUEDEXTA® sales increased to $18.4 million and $14.9 million, respectively, representing growth of 19% and 20% versus the previous quarter
  • Cash, cash equivalents, and restricted investments of $59.3 million as of December 31, 2012.
  • "Avanir delivered another strong quarter of growth with record NUEDEXTA sales and prescriptions," said Keith A. Katkin , president and CEO of Avanir.  "In addition, the clinical team has successfully executed our plan to move our next generation asset, AVP-786, through the first stage of the phase I clinical study, with encouraging results. With demonstrated success in the AVP-786 study, we now have two promising assets in clinical development, each of which has broad potential in a number of CNS indications."

    Fiscal 2013 First Quarter Results

  • Total net revenues for the quarter ended December 31, 2012 were $16.5 million, compared with $7.2 million for the comparable quarter in fiscal 2012, representing 130% year-over-year growth. Total net revenues consist of NUEDEXTA revenue and royalty revenue from Abreva®.
  • Total operating expenses, excluding cost of sales and share-based compensation were $25.3 million in the first quarter of fiscal 2013, compared with $21.7 million in the comparable period in fiscal 2012.
  • Cash used in operations was $12.7
    '/>"/>

  • SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Avanir Pharmaceuticals To Present at Three Conferences In May
    2. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
    3. Avanir Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
    4. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Third Quarter Financial Results And Conference Call
    5. Avanir Pharmaceuticals To Present At Two Investor Conferences In August
    6. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
    7. Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
    8. Avanir Pharmaceuticals To Present At UBS Global Life Sciences Conference
    9. Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates
    10. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
    11. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2015)... July 28, 2015 According to a ... Type (Device, Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, ... - Forecast to 2020", published by MarketsandMarkets, the European Injectable ... 2020 from $114.7 Billion in 2015, growing at a CAGR ... 230 market data T ables ...
    (Date:7/27/2015)... and WESTLAKE VILLAGE, Calif. , July ... ) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH ) ... has granted early termination of the waiting period under ... with respect to Allergan,s pending acquisition of KYTHERA.  ... On July 6, 2015, each of Allergan and KYTHERA ...
    (Date:7/27/2015)... , July 27, 2015  SeraCare Life ... diagnostics manufacturers, announced at the 2015 AACC Annual ... partnership agreement with ViveBio, LLC, a biotechnology company ... upon ViveST™ technology.  Products enabled with ViveST™ allow ... shelf stable format.  Under the terms of the ...
    Breaking Medicine Technology:European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 2European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 3European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 4Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 2Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 3Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 4Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 5Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 6Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 7Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 9SeraCare Life Sciences Announces Strategic Partnership with ViveBio to Enable Next Generation Preanalytic Products for the IVD Industry 2SeraCare Life Sciences Announces Strategic Partnership with ViveBio to Enable Next Generation Preanalytic Products for the IVD Industry 3
    ... Clinic has,clarified the methods of diagnosis and optimal ... of the brain and spinal cord that,often leads ... vasculitis,(PCNSV) can best be identified through a combination ... arteries), brain,biopsy and other laboratory studies., This ...
    ... at the World Muscle Society International Congress, ... PTC Therapeutics, Inc.,(PTC), a biopharmaceutical company focused ... drugs targeting,post-transcriptional control mechanisms, today announced additional ... PTC124 in patients with Duchenne muscular,dystrophy (DMD) ...
    Cached Medicine Technology:Mayo Clinic Clarifies Diagnosis and Treatment for Rare, Serious Blood Vessel Disease of Brain and Spinal Cord 2Mayo Clinic Clarifies Diagnosis and Treatment for Rare, Serious Blood Vessel Disease of Brain and Spinal Cord 3PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 4
    (Date:7/28/2015)... ... July 28, 2015 , ... Women fear developing Alzheimer's disease more than having ... attack, and stroke are treatable, but there is little an individual can do to ... part in a clinical trial, reports the July 2015 Harvard Women's Health Watch ...
    (Date:7/28/2015)... ... July 28, 2015 , ... A new study published ... Fibromyalgia, Study Says " sheds light on a possible new treatment option for people ... months of regular HBOT sessions, at least five per week, patients experienced a significant ...
    (Date:7/28/2015)... ... ... Most employers have been using multi-tier prescription drug plans for many years, ... increase in the use of 4-tier plans, which typically cover the highest cost drugs, ... expected to continue, according to UBA. , UBA’s survey finds that, since 2009, the ...
    (Date:7/28/2015)... ... July 28, 2015 , ... PeopleKeys today announced that their ... the EY Entrepreneur of the Year award. The award recognizes the important strides ... the innovative work they have done in incorporating new technology, processes, and procedures ...
    (Date:7/28/2015)... ... July 28, 2015 , ... Maryland Brain & Spine has adopted a new ... more service offerings, updated treatment techniques, and additional state-of-the art online resources for patients. ... invasive surgical treatment of brain and spine conditions. , “Adding the word ‘pain’ ...
    Breaking Medicine News(10 mins):Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 2Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 3Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 4Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 5Health News:Receiving Recognition for Compassionate Care and Innovative Processes: Celtic Healthcare CEO Arnie Burchianti Wins Regional EY Entrepreneur of the Year Award 2Health News:Receiving Recognition for Compassionate Care and Innovative Processes: Celtic Healthcare CEO Arnie Burchianti Wins Regional EY Entrepreneur of the Year Award 3Health News:Maryland Brain & Spine Announces New Specialty, New Name 2Health News:Maryland Brain & Spine Announces New Specialty, New Name 3Health News:Maryland Brain & Spine Announces New Specialty, New Name 4
    ... of anabolic steroids, more specifically anabolic androgen steroid (AAS) ... sebaceous glands. Sebaceous glands present in the skin // ... of the body surface. ,Anabolic steroids are ... to treat unwanted weight loss in patients with HIV. ...
    ... Teleradiology can soon offer a solution to the silent ... more than a good night’s sleep. // It ... subjected to middle of the night CT scans or ... emergency department. Such examinations have no doubt yielded the ...
    ... been raised against the use of Teflon. The Environmental Protection ... to make the substance nonsticky is a possible source of ... cookware was heated to more than 600 degrees Fahrenheit then ... ,Teflon was accidentally discovered in 1938. The Frenchman was ...
    ... A new law has come into existence to protect the ... McManis, J.D., IP and technology law expert, Thomas and Karole ... has come with various ideas. // This is mainly done ... promote the interest of the local communities. ...
    ... Sussman, Ph.D., professor anthropology in Arts & Sciences at Washington ... conditions, humans were actually peace loving race in earlier times. ... "Early Humans on the Menu," during the American Association for ... on February 18. ,In his new ...
    ... children that are raised in Foster homes better off ... children from the orphanages don’t grow to their full ... not irreversible - when the same children were put ... areas. ,Romania’s experiment of Foster homes, that included ...
    Cached Medicine News:Health News:International Teleradiology: The Future Of Radiologic Diagnosis 2Health News:Early Man Was A Prey Rather Than A Predator 2
    ... These precision 4mL PYREX volumetric ... "To Contain" (TC - bottom ... - top line) to specifications ... Pipets are color-coded with colored ...
    ... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
    Inquire...
    ... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
    Medicine Products: